October 24, 2016
MSD’s immuno-oncology drug Keytruda (pembrolizumab) is expected to skip the upcoming round of reimbursement listing in November amid continued uncertainties over the re-pricing of rival med Opdivo (nivolumab), sources familiar with the matter told Jiho. Keytruda was approved in September...read more